Overview

* Travere Q2 2025 product sales rise 82% to $94.8 mln, driven by FILSPARI

* Total revenue for Q2 2025 reaches $114.4 mln, includes $17.5 mln milestone

* Net loss narrows to $12.8 mln from $70.4 mln in Q2 2024

Outlook

* Travere expects August 2025 PDUFA date for FILSPARI REMS modification

* Company anticipates January 2026 FDA decision on FILSPARI for FSGS

Result Drivers

* FILSPARI SALES GROWTH - U.S. net product sales of FILSPARI grew 165% year-over-year to $71.9 mln, driven by increased momentum in the IgAN market

* MILESTONE PAYMENT - Total revenue includes $17.5 mln milestone payment from CSL Vifor

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $94.84

Product mln

Sales

Q2 EPS -$0.14

Q2 Net -$12.76

Income mln

Q2 $127.10

Operatin mln

g

Expenses

Q2 -$12.65

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Travere Therapeutics Inc ( TVTX ) is $30.00, about 44.4% above its August 5 closing price of $16.68

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)